Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present virtually at the 42nd Annual Cowen Health Care Conference.
Singular Genomics’ management is scheduled to participate in a fireside chat Monday, March 7, 2022, at 11:10 a.m. Pacific Time / 2:10 p.m. Eastern Time.
Investors and other interested parties are invited to listen to a live and recorded webcast of the presentation on the News & Events section of the company’s investor relations website at https://investor.singulargenomics.com/news-events/event-calendar.
About Singular Genomics Systems, Inc.
Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. Our mission is to accelerate genomics for the advancement of science and medicine. Our Singular Sequencing Engine is the foundational platform technology that forms the basis of our products as well as our core product tenets: power, speed, flexibility, and accuracy. We are currently developing two products that are purpose built to target applications in which these core product tenets matter most. Our first product, the G4, targets the NGS market. Our second product in development, the PX, combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument to offer a versatile multiomics solution.
Investor Contact
Matt Clawson
949-370-8500
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Dan Budwick, 1AB
973-271-6085
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$20.01 |
Daily Volume: | 0 |
Market Cap: | US$50.830M |
February 24, 2025 September 19, 2024 August 13, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load